Atherosclerosis
Volume 186, Issue 1 , Pages 38-53 , May 2006

The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis

Received 4 January 2005 ,Revised 21 June 2005 ,Accepted 23 June 2005.

References 

  1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  2. Stary HC. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis. 1987;64:91–108
  3. Stary HC. Changes in the cells of atherosclerotic lesions as advanced lesions evolve in coronary arteries of children and young adults. In:  Glagov S,  Newman WP,  Schaffer SA editor. Pathobiology of the human atherosclerotic plaque. Springer-Verlag: New York; 1990;p. 93–106
  4. Malinauskas RA, Herrmann RA, Truskey GA. The distribution of intimal white blood cells in the normal rabbit aorta. Atherosclerosis. 1995;115:147–163
  5. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol. 1996;149:359–366
  6. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284:2–13
  7. Massague J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem. 1993;62:515–541
  8. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14–30
  9. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555–1562
  10. Starkey RH, Cohen S, Orth DN. Epidermal growth factor: identification of a new hormone in human urine. Science. 1975;189:800–802
  11. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193–216
  12. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265:7709–7712
  13. De Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA. 1978;75:4001–4005
  14. Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci USA. 1983;80:6264–6268
  15. Winkler ME, O’Connor L, Winget M, Fendly B. Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry. 1989;28:6373–6378
  16. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936–939
  17. Shing Y, Christofori G, Hanahan D, et al. Betacellulin: a mitogen from pancreatic beta cell tumors. Science. 1993;259:1604–1607
  18. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA. 1988;85:6528–6532
  19. Johnson GR, Kannan B, Shoyab M, Stromberg K. Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells. J Biol Chem. 1993;268:2924–2931
  20. Toyoda H, Komurasaki T, Uchida D, Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J. 1997;326(Pt 1):69–75
  21. Toyoda H, Komurasaki T, Uchida D, et al. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem. 1995;270:7495–7500
  22. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Kumble KD. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem. 2001;276:18265–18271
  23. Lee DC, Fenton SE, Berkowitz EA, Hissong MA. Transforming growth factor alpha: expression, regulation, and biological activities. Pharmacol Rev. 1995;47:51–85
  24. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta. 1997;1333:F179–F199
  25. Thompson SA, Higashiyama S, Wood K, et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem. 1994;269:2541–2549
  26. Thorne BA, Plowman GD. The heparin-binding domain of amphiregulin necessitates the precursor pro-region for growth factor secretion. Mol Cell Biol. 1994;14:1635–1646
  27. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science. 1989;243:1074–1076
  28. Miura K, Doura H, Aizawa T, et al. Solution structure of betacellulin, a new member of EGF-family ligands. Biochem Biophys Res Commun. 2002;294:1040–1046
  29. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science. 1992;256:1205–1210
  30. Carraway KL, Weber JL, Unger MJ, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature. 1997;387:512–516
  31. Chang H, Riese DJ, Gilbert W, Stern DF, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature. 1997;387:509–512
  32. Zhang D, Sliwkowski MX, Mark M, et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA. 1997;94:9562–9567
  33. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene. 1999;18:2681–2689
  34. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 2000;16:83–87
  35. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281–1284
  36. Burgess AW. Epidermal growth factor and transforming growth factor alpha. Br Med Bull. 1989;45:401–424
  37. Hinkle CL, Mohan MJ, Lin P, et al. Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha). Biochemistry. 2003;42:2127–2136
  38. Yu WH, Woessner JF, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 2002;16:307–323
  39. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997;272:31730–31737
  40. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164:769–779
  41. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 1998;17:7260–7272
  42. Tanaka M, Nanba D, Mori S, et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem. 2004;279:41950–41959
  43. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35–40
  44. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 2003;22:2411–2421
  45. Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71:1–20
  46. Hunter T, Cooper JA. Protein-tyrosine kinases. Annu Rev Biochem. 1985;54:897–930
  47. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418–425
  48. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984;307:521–527
  49. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31–53
  50. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637–643
  51. Bhargava G, Rifas L, Makman MH. Presence of epidermal growth factor receptors and influence of epidermal growth factor on proliferation and aging in cultured smooth muscle cells. J Cell Physiol. 1979;100:365–374
  52. Gospodarowicz D, Brown KD, Birdwell CR, Zetter BR. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol. 1978;77:774–788
  53. Oka Y, Orth DN. Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest. 1983;72:249–259
  54. Styren SD, DeKosky ST, Rogers J, Mufson EJ. Epidermal growth factor receptor expression in demented elderly: localization to vascular endothelial cells of brain, pituitary and skin. Brain Res. 1993;615:181–190
  55. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 1994;91:2890–2894
  56. Matsumoto S, Kishida K, Shimomura I, et al. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun. 2002;292:781–786
  57. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci USA. 1994;91:1069–1073
  58. Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP, Quertermous T, Lee ME. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J Biol Chem. 1992;267:9467–9469
  59. Derynck R. The physiology of transforming growth factor-alpha. Adv Cancer Res. 1992;58:27–52
  60. Madtes DK, Raines EW, Sakariassen KS, et al. Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell. 1988;53:285–293
  61. Mueller SG, Paterson AJ, Kudlow JE. Transforming growth factor alpha in arterioles: cell surface processing of its precursor by elastases. Mol Cell Biol. 1990;10:4596–4602
  62. Rappolee DA, Mark D, Banda MJ, Werb Z. Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. Science. 1988;241:708–712
  63. Dunbar AJ, Goddard C. Structure–function and biological role of betacellulin. Int J Biochem Cell Biol. 2000;32:805–815
  64. Riese DJ, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene. 1996;12:345–353
  65. Mograbi B, Rochet N, Imbert V, et al. Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw. 1997;8:73–81
  66. Koo BH, Kim DS. Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin. J Biol Chem. 2003;278:52578–52586
  67. Lax I, Mitra AK, Ravera C, et al. Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain. J Biol Chem. 1991;266:13828–13833
  68. Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J. 1989;8:421–427
  69. Cadena DL, Gill GN. Receptor tyrosine kinases. FASEB J. 1992;6:2332–2337
  70. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203–212
  71. Kashles O, Szapary D, Bellot F, Ullrich A, Schlessinger J, Schmidt A. Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. Proc Natl Acad Sci USA. 1988;85:9567–9571
  72. Riedel H, Dull TJ, Honegger AM, Schlessinger J, Ullrich A. Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors. EMBO J. 1989;8:2943–2954
  73. Van der Heyden MA, Nievers M, Verkleij AJ, Boonstra J, Van Bergen en Henegouwen PM. Identification of an intracellular domain of the EGF receptor required for high-affinity binding of EGF. FEBS Lett. 1997;410:265–268
  74. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453–481
  75. Honegger AM, Dull TJ, Felder S, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein–tyrosine kinase activity and alters cellular routing. Cell. 1987;51:199–209
  76. Moolenaar WH, Bierman AJ, Tilly BC, et al. A point mutation at the ATP-binding site of the EGF-receptor abolishes signal transduction. EMBO J. 1988;7:707–710
  77. Prywes R, Livneh E, Ullrich A, Schlessinger J. Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalisation. EMBO J. 1986;5:2179–2190
  78. Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature. 1987;328:820–823
  79. Gamou S, Shimizu N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett. 1995;357:161–164
  80. Bae YS, Kang SW, Seo MS, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem. 1997;272:217–221
  81. Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem. 1998;273:15366–15372
  82. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature. 1984;311:483–485
  83. Margolis BL, Lax I, Kris R, et al. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem. 1989;264:10667–10671
  84. Walton GM, Chen WS, Rosenfeld MG, Gill GN. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem. 1990;265:1750–1754
  85. Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol. 2001;311:1011–1026
  86. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA. 1994;91:1500–1504
  87. Yarden Y, Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry. 1987;26:1434–1442
  88. Marciniak DJ, Moragoda L, Mohammad RM, et al. Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology. 2003;124:1337–1347
  89. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001;12:745–760
  90. Modjtahedi H, Moscatello DK, Box G, et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer. 2003;105:273–280
  91. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem. 1996;271:6071–6076
  92. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997;16:1268–1278
  93. Anklesaria P, Teixido J, Laiho M, Pierce JH, Greenberger JS, Massague J. Cell–cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proc Natl Acad Sci USA. 1990;87:3289–3293
  94. Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 2000;11:335–344
  95. Hurwitz DR, Emanuel SL, Nathan MH, et al. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem. 1991;266:22035–22043
  96. Lemmon MA, Bu Z, Ladbury JE, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimmer. EMBO J. 1997;16:281–294
  97. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225
  98. Sherrill JM, Kyte J. Activation of epidermal growth factor receptor by epidermal growth factor. Biochemistry. 1996;35:5705–5718
  99. Ge G, Wu J, Wang Y, Lin Q. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase. Biochem Biophys Res Commun. 2002;290:914–920
  100. Tanner KG, Kyte J. Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor. J Biol Chem. 1999;274:35985–35990
  101. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 1994;19:459–463
  102. Greenfield C, Hiles I, Waterfield MD, et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 1989;8:4115–4123
  103. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80:213–223
  104. Deb TB, Su L, Wong L, et al. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J Biol Chem. 2001;276:15554–15560
  105. King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high-affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem. 1982;257:3053–3060
  106. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16:1647–1655
  107. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G-protein-transactivated EGF receptor. EMBO J. 1997;16:7032–7044
  108. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557–560
  109. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol. 1999;11:177–183
  110. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884–888
  111. Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci. 2003;24:239–244
  112. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:489–495
  113. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 2004;15:513–520
  114. Kim JH, Kim JH, Song WK, Kim JH, Chun JS. Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in rat-2 cells. IUBMB Life. 2000;50:119–124
  115. Le Stunff H, Mikami A, Giussani P, et al. Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J Biol Chem. 2004;279:34290–34297
  116. Zhao D, Letterman J, Schreiber BM. beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G-protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell proliferation. J Biol Chem. 2001;276:30579–30588
  117. Argast GM, Campbell JS, Brooling JT, Fausto N. Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication. J Biol Chem. 2004;279:34530–34536
  118. Schraufstatter IU, Trieu K, Zhao M, Rose DM, Terkeltaub RA, Burger M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol. 2003;171:6714–6722
  119. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res. 2004;2:514–522
  120. Kanda Y, Mizuno K, Kuroki Y, Watanabe Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol. 2001;132:1657–1664
  121. Iwasaki H, Eguchi S, Marumo F, Hirata Y. Endothelin-1 stimulates DNA synthesis of vascular smooth-muscle cells through transactivation of epidermal growth factor receptor. J Cardiovasc Pharmacol. 1998;31(Suppl. 1):S182–S184
  122. Cunnick JM, Dorsey JF, Standley T, et al. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem. 1998;273:14468–14475
  123. Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal. 2003;15:945–953
  124. Keely SJ, Uribe JM, Barrett KE. Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion. J Biol Chem. 1998;273:27111–27117
  125. Tsai W, Morielli AD, Peralta EG. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J. 1997;16:4597–4605
  126. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem. 2003;278:26202–26207
  127. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J Cell Biol. 1999;146:697–702
  128. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol. 2001;21:6387–6394
  129. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci. 1993;18:128–131
  130. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem. 1993;62:851–891
  131. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992;70:431–442
  132. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature. 1996;379:560–564
  133. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol. 2000;20:1448–1459
  134. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1999;11:184–189
  135. Lund KA, Lazar CS, Chen WS, et al. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem. 1990;265:20517–20523
  136. Lin CR, Chen WS, Lazar CS, et al. Protein kinase C phosphorylation at Thr 654 of the unoccupied EGF receptor and EGF binding regulate functional receptor loss by independent mechanisms. Cell. 1986;44:839–848
  137. Liu P, Anderson RG. Spatial organization of EGF receptor transmodulation by PDGF. Biochem Biophys Res Commun. 1999;261:695–700
  138. Wiley HS. Trafficking of the ErbB receptors and its influence on signalling. Exp Cell Res. 2003;284:78–88
  139. Yamabhai M, Anderson RG. Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts. J Biol Chem. 2002;277:24843–24846
  140. Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998;67:199–225
  141. Lai EC. Lipid rafts make for slippery platforms. J Cell Biol. 2003;162:365–370
  142. Roepstorff K, Thomsen P, Sandvig K, van Deurs B. Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding. J Biol Chem. 2002;277:18954–18960
  143. Waugh MG, Lawson D, Hsuan JJ. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. Biochem J. 1999;337(Pt 3):591–597
  144. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272:30429–30438
  145. Matveev SV, Smart EJ. Heterologous desensitization of EGF receptors and PDGF receptors by sequestration in caveolae. Am J Physiol Cell Physiol. 2002;282:C935–C946
  146. Pike LJ, Casey L. Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry. 2002;41:10315–10322
  147. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572
  148. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–3167
  149. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998;17:3385–3397
  150. Leof EB. Growth factor receptor signalling: location, location, location. Trends Cell Biol. 2000;10:343–348
  151. Lamaze C, Schmid SL. Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase. J Cell Biol. 1995;129:47–54
  152. Sorkin A, Carpenter G. Dimerization of internalized epidermal growth factor receptors. J Biol Chem. 1991;266:23453–23460
  153. Yamanaka Y, Hayashi K, Komurasaki T, Morimoto S, Ogihara T, Sobue K. EGF family ligand-dependent phenotypic modulation of smooth muscle cells through EGF receptor. Biochem Biophys Res Commun. 2001;281:373–377
  154. Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis A. High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 1993;99:253–259
  155. Ko Y, Stiebler H, Nickenig G, Wieczorek AJ, Vetter H, Sachinidis A. Synergistic action of angiotensin II, insulin-like growth factor-I, and transforming growth factor-beta on platelet-derived growth factor-BB, basic fibroblastic growth factor, and epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Am J Hypertens. 1993;6:496–499
  156. Mitsumata M, Gamou S, Shimizu N, Yoshida Y. Response of atherosclerotic intimal smooth muscle cells to epidermal growth factor in vitro. Arterioscler Thromb. 1994;14:1364–1371
  157. Gui Y, Zheng XL. Epidermal growth factor induction of phenotype-dependent cell cycle arrest in vascular smooth muscle cells is through the mitogen-activated protein kinase pathway. J Biol Chem. 2003;278:53017–53025
  158. Ullian ME, Raymond JR, Willingham MC, Paul RV. Regulation of vascular angiotensin II receptors by EGF. Am J Physiol. 1997;273:C1241–C1249
  159. Pan Z, Kravchenko VV, Ye RD. Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. Correlation with an increased kappa B binding activity. J Biol Chem. 1995;270:7787–7790
  160. Dluz SM, Higashiyama S, Damm D, Abraham JA, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen. J Biol Chem. 1993;268:18330–18334
  161. Temizer DH, Yoshizumi M, Perrella MA, Susanni EE, Quertermous T, Lee ME. Induction of heparin-binding epidermal growth factor-like growth factor mRNA by phorbol ester and angiotensin II in rat aortic smooth muscle cells. J Biol Chem. 1992;267:24892–24896
  162. Miyagawa J, Higashiyama S, Kawata S, et al. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest. 1995;95:404–411
  163. Nakata A, Miyagawa J, Yamashita S, et al. Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis. Circulation. 1996;94:2778–2786
  164. Reape TJ, Wilson VJ, Kanczler JM, Ward JP, Burnand KG, Thomas CR. Detection and cellular localization of heparin-binding epidermal growth factor-like growth factor mRNA and protein in human atherosclerotic tissue. J Mol Cell Cardiol. 1997;29:1639–1648
  165. Nishida M, Miyagawa J, Yamashita S, et al. Localization of CD9, an enhancer protein for proheparin-binding epidermal growth factor-like growth factor, in human atherosclerotic plaques: possible involvement of juxtacrine growth mechanism on smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol. 2000;20:1236–1243
  166. Ouchi N, Kihara S, Yamashita S, et al. Role of membrane-anchored heparin-binding epidermal growth factor-like growth factor and CD9 on macrophages. Biochem J. 1997;328(Pt 3):923–928
  167. Peifley KA, Alberts GF, Hsu DK, Feng SL, Winkles JA. Heparin-binding epidermal growth factor-like growth factor regulates fibroblast growth factor-2 expression in aortic smooth muscle cells. Circ Res. 1996;79:263–270
  168. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001;947:42–54
  169. Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation. 2003;108:2679–2688
  170. Nakano T, Raines EW, Abraham JA, et al. Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells. J Biol Chem. 1993;268:22941–22947
  171. Asakawa H, Miyagawa J, Higashiyama S, et al. High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells. Cell Biochem Funct. 1996;14:181–186
  172. Arkonac BM, Foster LC, Sibinga NE, et al. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem. 1998;273:4400–4405
  173. Nishi E, Kume N, Ochi H, et al. Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes. Circ Res. 1997;80:638–644
  174. Tamura R, Miyagawa J, Nishida M, et al. Immunohistochemical localization of betacellulin, a member of epidermal growth factor family, in atherosclerotic plaques of human aorta. Atherosclerosis. 2001;155:413–423
  175. Kato M, Inazu T, Kawai Y, et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun. 2003;301:1109–1115
  176. Shin HS, Lee HJ, Nishida M, et al. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res. 2003;93:302–310
  177. Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA. 1999;96:1633–1638
  178. Nanney LB, Stoscheck CM, King LE. Characterization of binding and receptors for epidermal growth factor in smooth muscle. Cell Tissue Res. 1988;254:125–132
  179. Tomita M, Hirata Y, Uchihashi M, Fujita T. Characterization of epidermal growth factor receptors in cultured vascular smooth muscle cells of rat aorta. Endocrinol Jpn. 1986;33:177–184
  180. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966–990
  181. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993;122:933–940
  182. Nolte C, Kirchhoff F, Kettenmann H. Epidermal growth factor is a motility factor for microglial cells in vitro: evidence for EGF receptor expression. Eur J Neurosci. 1997;9:1690–1698
  183. Scholes AG, Hagan S, Hiscott P, Damato BE, Grierson I. Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. Arch Ophthalmol. 2001;119:373–377
  184. Eales-Reynolds LJ, Laver H, Mojtahedi H. Evidence for the expression of the EGF receptor on human monocytic cells. Cytokine. 2001;16:169–172
  185. Lamb DJ, Modjtahedi H, Plant NJ, Ferns GA. EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques. Atherosclerosis. 2004;176:21–26
  186. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA. 1990;87:4600–4604
  187. Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 1990;10:680–687
  188. Namba K, Nishio M, Mori K, et al. Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes. Cell Immunol. 2001;213:104–113
  189. Worley JR, Baugh MD, Hughes DA, et al. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem. 2003;278:51340–51346
  190. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol. 1998;9:413–423
  191. Suzuki A, Kadota N, Hara T, et al. Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src. Oncogene. 2000;19:5842–5850
  192. Lee JS, Ro JS, Eisbruch A, et al. Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor gene. Cancer Res. 1988;48:4045–4048
  193. Pavlovic M, Kay PH, Moriuchi J, Jacobsen PF, Papadimitriou JM. TaqI polymorphism of the epidermal growth factor receptor gene in Caucasoids and Japanese. Hum Hered. 1993;43:39–44
  194. Lopez ME, Kobrin MS, Moriai T, et al. Single-strand conformation polymorphism analysis of the epidermal growth factor receptor at codon 497. Pancreas. 1996;12:216–220
  195. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999;274:13176–13180
  196. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res. 2004;64:7–12
  197. Magistroni R, Manfredini P, Furci L, et al. Epidermal growth factor receptor polymorphism and autosomal dominant polycystic kidney disease. J Nephrol. 2003;16:110–115
  198. Liu W, Innocenti F, Chen P, Das S, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003;9:1009–1012
  199. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–2799
  200. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989;32:2344–2352
  201. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988;242:933–935
  202. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem. 1989;264:14503–14509
  203. Bianco R, Daniele G, Ciardiello F, Tortora G. Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets. 2005;6:275–287
  204. Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets. 2005;6:259–274
  205. Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev. 2005;24:129–146
  206. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689–708
  207. Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs. 2003;8:501–514
  208. Fry DW. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res. 2003;284:131–139
  209. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10:1212–1218
  210. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol. 2003;532:235–246
  211. Allen LF, Eiseman IA, Fry DW, Lenehan PF. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003;30:65–78
  212. Dewji MR. Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?. J Chemother. 2004;16(Suppl. 4):44–48
  213. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851–867
  214. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85–94
  215. Ryan AJ, Wedge SR. ZD6474—a novel inhibitor of VGEFR and EGFR tyrosine kinase activity. Br J Cancer. 2005;92(Suppl. 1):S6–S13
  216. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996;19:419–427
  217. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc.). 2005;41:107–127
  218. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984–990
  219. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17–23
  220. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004;22:175–184
  221. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother. 2000;49:493–503
  222. Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer. 1996;73:228–235

PII: S0021-9150(05)00445-4

doi: 10.1016/j.atherosclerosis.2005.06.038

Atherosclerosis
Volume 186, Issue 1 , Pages 38-53 , May 2006

Article Tools

* Image Usage & Resolution